Influenza Vaccination in Orthotopic Liver Transplant Recipients: Absence of Post Administration ALT Elevation

[Guest guest]

Am J Transplant. 2004 Nov;4(11):1805-9.

Influenza Vaccination in Orthotopic Liver Transplant Recipients: Absence of

Post Administration ALT Elevation.

Lawal A, Basler C, Branch A, Gutierrez J, Schwartz M, Schiano TD.

Department of Medicine and Division of Liver Diseases, The Mount Sinai

Medical Center, New York, NY, USA.

Influenza vaccination has reduced life-threatening complications from

influenza virus infection in adult liver transplant recipients. We evaluated

changes in aminotransferase level and immunogenicity of influenza

vaccination in liver transplant recipients. Fifty-one liver transplant

recipients were administered a standard dose of the 2002-2003 inactivated

trivalent influenza vaccine. ALT values were measured at baseline, 1 week

and 4-6 weeks postvaccination. Antibody responses to each component of the

vaccine were measured at baseline and after 4-6 weeks by a hemagglutination

inhibition (HAI) assay. Response was defined as an HAI titer >/= 1: 40

and/or a 4-fold increase in antibody titers from baseline. An ALT elevation

was defined as a rise of >/= 50% from baseline. There was no difference in

the median rise in ALT value between seroconverters and nonseroconverters. A

significant number of recipients developed potentially protective antibody

titers (p-value < 0.0001). At less than 4 months post transplantation, 1/7

(14%), at 4-12 months, 6/9 (67%), and after 12 months, 30/35 (86%) subjects

responded to the H1 strain. Of 51 recipients, one HCV (-) recipients

vaccinated within 3 months of transplantation developed acute cellular

rejection. Influenza virus vaccination is not associated with allograft

rejection or ALT flares in liver transplant recipients.

PMID: 15476480 [PubMed - in process]

[Guest guest]

Am J Transplant. 2004 Nov;4(11):1805-9.

Influenza Vaccination in Orthotopic Liver Transplant Recipients: Absence of

Post Administration ALT Elevation.

Lawal A, Basler C, Branch A, Gutierrez J, Schwartz M, Schiano TD.

Department of Medicine and Division of Liver Diseases, The Mount Sinai

Medical Center, New York, NY, USA.

Influenza vaccination has reduced life-threatening complications from

influenza virus infection in adult liver transplant recipients. We evaluated

changes in aminotransferase level and immunogenicity of influenza

vaccination in liver transplant recipients. Fifty-one liver transplant

recipients were administered a standard dose of the 2002-2003 inactivated

trivalent influenza vaccine. ALT values were measured at baseline, 1 week

and 4-6 weeks postvaccination. Antibody responses to each component of the

vaccine were measured at baseline and after 4-6 weeks by a hemagglutination

inhibition (HAI) assay. Response was defined as an HAI titer >/= 1: 40

and/or a 4-fold increase in antibody titers from baseline. An ALT elevation

was defined as a rise of >/= 50% from baseline. There was no difference in

the median rise in ALT value between seroconverters and nonseroconverters. A

significant number of recipients developed potentially protective antibody

titers (p-value < 0.0001). At less than 4 months post transplantation, 1/7

(14%), at 4-12 months, 6/9 (67%), and after 12 months, 30/35 (86%) subjects

responded to the H1 strain. Of 51 recipients, one HCV (-) recipients

vaccinated within 3 months of transplantation developed acute cellular

rejection. Influenza virus vaccination is not associated with allograft

rejection or ALT flares in liver transplant recipients.

PMID: 15476480 [PubMed - in process]

[Guest guest]

Am J Transplant. 2004 Nov;4(11):1805-9.

Influenza Vaccination in Orthotopic Liver Transplant Recipients: Absence of

Post Administration ALT Elevation.

Lawal A, Basler C, Branch A, Gutierrez J, Schwartz M, Schiano TD.

Department of Medicine and Division of Liver Diseases, The Mount Sinai

Medical Center, New York, NY, USA.

Influenza vaccination has reduced life-threatening complications from

influenza virus infection in adult liver transplant recipients. We evaluated

changes in aminotransferase level and immunogenicity of influenza

vaccination in liver transplant recipients. Fifty-one liver transplant

recipients were administered a standard dose of the 2002-2003 inactivated

trivalent influenza vaccine. ALT values were measured at baseline, 1 week

and 4-6 weeks postvaccination. Antibody responses to each component of the

vaccine were measured at baseline and after 4-6 weeks by a hemagglutination

inhibition (HAI) assay. Response was defined as an HAI titer >/= 1: 40

and/or a 4-fold increase in antibody titers from baseline. An ALT elevation

was defined as a rise of >/= 50% from baseline. There was no difference in

the median rise in ALT value between seroconverters and nonseroconverters. A

significant number of recipients developed potentially protective antibody

titers (p-value < 0.0001). At less than 4 months post transplantation, 1/7

(14%), at 4-12 months, 6/9 (67%), and after 12 months, 30/35 (86%) subjects

responded to the H1 strain. Of 51 recipients, one HCV (-) recipients

vaccinated within 3 months of transplantation developed acute cellular

rejection. Influenza virus vaccination is not associated with allograft

rejection or ALT flares in liver transplant recipients.

PMID: 15476480 [PubMed - in process]

[Guest guest]

Am J Transplant. 2004 Nov;4(11):1805-9.

Influenza Vaccination in Orthotopic Liver Transplant Recipients: Absence of

Post Administration ALT Elevation.

Lawal A, Basler C, Branch A, Gutierrez J, Schwartz M, Schiano TD.

Department of Medicine and Division of Liver Diseases, The Mount Sinai

Medical Center, New York, NY, USA.

Influenza vaccination has reduced life-threatening complications from

influenza virus infection in adult liver transplant recipients. We evaluated

changes in aminotransferase level and immunogenicity of influenza

vaccination in liver transplant recipients. Fifty-one liver transplant

recipients were administered a standard dose of the 2002-2003 inactivated

trivalent influenza vaccine. ALT values were measured at baseline, 1 week

and 4-6 weeks postvaccination. Antibody responses to each component of the

vaccine were measured at baseline and after 4-6 weeks by a hemagglutination

inhibition (HAI) assay. Response was defined as an HAI titer >/= 1: 40

and/or a 4-fold increase in antibody titers from baseline. An ALT elevation

was defined as a rise of >/= 50% from baseline. There was no difference in

the median rise in ALT value between seroconverters and nonseroconverters. A

significant number of recipients developed potentially protective antibody

titers (p-value < 0.0001). At less than 4 months post transplantation, 1/7

(14%), at 4-12 months, 6/9 (67%), and after 12 months, 30/35 (86%) subjects

responded to the H1 strain. Of 51 recipients, one HCV (-) recipients

vaccinated within 3 months of transplantation developed acute cellular

rejection. Influenza virus vaccination is not associated with allograft

rejection or ALT flares in liver transplant recipients.

PMID: 15476480 [PubMed - in process]